DrugCards

24/02/2026

💡𝗪𝗵𝘆 𝗦𝗼𝗺𝗲 𝗣𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲𝘀 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲 𝗪𝗶𝗹𝗹 𝗡𝗲𝘃𝗲𝗿 𝗖𝗵𝗮𝗻𝗴𝗲
AI is revolutionising how we handle case intake. Automation accelerates literature 📚screening. Global databases are more connected than ever.
☝️Yet, despite all this innovation, some things remain constant. Patient safety. Clinical judgment. Documentation. Regulatory compliance. Ethical responsibility. No AI, no automation, no global database can replace the human expertise behind every decision.

We often focus on numbers - case reports, signals, trends - but behind every ICSR is a 👤real person. Every report matters. Every assessment matters. Every decision matters.
💬In our latest blog, we dive into the core principles of pharmacovigilance that will never change - and why they remain the foundation of this fast-evolving field: https://drug-card.io/blog/core-principles-of-pharmacovigilance-that-will-never-change/

18/02/2026

🇪🇸 DrugCard at European Drug Safety & AI 2026
Can’t wait to see you there 🙌🏻

17/02/2026

🎨𝗧𝗵𝗲 𝗔𝗿𝘁 𝗼𝗳 𝗝𝘂𝗱𝗴𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲
Pharmacovigilance is not about easy cases.
It is about the report 📑that raises more questions than answers.
The patient has three comorbidities and five concomitant 💊drugs.
The timeline that almost fits. And still, a decision must be made. Clear. Defensible. Regulator-ready.

🎤We spoke with Mircea Ciuca, who regularly handles high-impact and ambiguous safety cases. In our latest blog interview, he shares how he navigates complexity in the real world - from reconstructing incomplete clinical narratives to expressing uncertainty in a way regulators can trust.
💡If you work in PV, this one will feel very familiar: https://drug-card.io/blog/decision-making-in-pv-how-experts-evaluate-uncertain-safety-data/

10/02/2026

🤖𝗔𝗜 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲 𝗶𝘀 𝗲𝘃𝗲𝗿𝘆𝘄𝗵𝗲𝗿𝗲, 𝗯𝘂𝘁 𝗰𝗮𝗻 𝗶𝘁 𝗿𝗲𝗮𝗹𝗹𝘆 𝗿𝗲𝗽𝗹𝗮𝗰𝗲 𝗵𝘂𝗺𝗮𝗻 𝗷𝘂𝗱𝗴𝗺𝗲𝗻𝘁?
We rely on automation to process vast volumes of case reports, screen 📚literature, and detect signals faster. Yet some things AI can’t do in pharmacovigilance.

💡Understanding the limits of AI isn’t about resisting technology. It’s about designing smarter workflows where AI supports human expertise, not replaces it.
👉Read the full article to see why human judgment remains central to patient safety and regulatory compliance: https://drug-card.io/blog/what-ai-can-t-do-in-pharmacovigilance-and-why-it-still-matters/

03/02/2026

𝗥𝗲𝗱 𝗙𝗹𝗮𝗴𝘀 🚩𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝗛𝗼𝘄 𝘁𝗼 𝗦𝗽𝗼𝘁 𝗧𝗿𝗼𝘂𝗯𝗹𝗲 𝗕𝗲𝗳𝗼𝗿𝗲 𝗜𝘁 𝗦𝗽𝗼𝘁𝘀 𝗬𝗼𝘂
From dating apps to office politics, spotting red flags is in fashion. In pharmacovigilance, it’s far more than a trend - it’s a critical responsibility. Miss a delay in reporting⏰, a spike in adverse events, or hidden safety data, and your patients - and regulators - notice.

🧐Are you confident your team is seeing all the red flags in your safety data?
👉Read the full article on our blog: https://drug-card.io/blog/5-red-flags-in-pharmacovigilance-every-safety-team-must-recognise/

27/01/2026

𝗟𝗶𝘁𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗦𝗮𝗳𝗲𝘁𝘆 𝘄𝗶𝘁𝗵 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗼𝗻, 𝗗𝗲𝗹𝗲𝗴𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗘𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻
Every day, thousands of 📑new articles, case reports, and regulatory updates 📕are published - any of which could contain critical safety information.

👨🏻‍💻How should PV teams handle this flood of data? Should you automate, delegate, or eliminate parts of your literature monitoring process? Each choice impacts efficiency, compliance, and patient safety.
The question isn’t whether to adapt - it’s how to do it smartly.

💡Read the full article and discover strategies to streamline your literature monitoring workflow: https://drug-card.io/blog/literature-monitoring-for-drug-safety-automate-delegate-or-eliminate/

20/01/2026

𝗔𝗜 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 “𝗲𝘅𝗽𝗲𝗿𝗶𝗺𝗲𝗻𝘁𝗮𝗹” - 𝗶𝘁’𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗲𝗱.
🤝EMA and FDA have agreed on the Principles of Good AI Practice in Drug Development.
This is a significant signal for the future of pharmacovigilance🚀.

At DrugCard, we’ve been building an 🦾AI-powered pharmacovigilance platform with these principles in mind - long before they became regulatory expectations.
AI is moving from “nice to have” to “must be done right.”

👉Read the full article on the DrugCard blog and see how regulation is catching up with innovation: https://drug-card.io/blog/principles-of-good-ai-practice-in-drug-development-ema-and-fda-set-a-common-framework/

13/01/2026

🎬 Kyiv Drug Safety Day — Event Vlog is Live!

We’re excited to share the official vlog from Kyiv Drug Safety Day, the first practical conference in Ukraine dedicated to automation and AI in pharmacovigilance.

This video captures the real atmosphere of the event — expert talks, panel discussions, meaningful conversations, and the launch of the Secret Drug Safety Club UA. Most importantly, it reflects the people and community behind this initiative.

Thank you to everyone who joined us in Kyiv and helped make this day so impactful.

If you couldn’t attend — we hope this vlog gives you a glimpse into the Ukrainian PV community and the values we’re building together.

👉 Watch the video:

Join us behind the scenes of Kyiv Drug Safety Day — the first practical conference in Ukraine dedicated to automation and AI in pharmacovigilance.This vlog c...

13/01/2026

🤝𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗽𝗵𝗮𝗿𝗺𝗮 𝘁𝗲𝗮𝗺𝘀 𝗮𝘀𝗸 𝗳𝗼𝗿 𝗵𝗲𝗹𝗽 - 𝗮𝗻𝗱 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗹𝗶𝘀𝘁𝗲𝗻𝘀?
Many regulatory and pharmacovigilance teams struggle with one hidden but critical task: tracking changes in 📄 reference SmPCs.
🪫Manual checks. File comparisons. Missed updates. Compliance risks.
💡When several DrugCard clients raised this challenge, we didn’t add it to a future roadmap.
𝐖𝐞 𝐛𝐮𝐢𝐥𝐭 𝐚 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 - 𝐚𝐧𝐝 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐞𝐝 𝐢𝐭 𝐢𝐧 𝐣𝐮𝐬𝐭 𝟏.𝟓 𝐦𝐨𝐧𝐭𝐡𝐬.
Our new Reference SmPC change monitoring automatically detects updates in the Ukrainian State Register of Medicines - so teams can act faster, stay compliant, and reduce risk 🚀.

✅Read the details in the blog: https://drug-card.io/blog/how-drugcard-delivered-reference-smpc-change-monitoring-in-just-1-5-months/

06/01/2026

2025 was a year of growth, learning, and building for DrugCard.

In this video, we share DrugCard’s 2025 results in numbers — from key platform metrics and product milestones to new automation modules, industry events we attended, and initiatives we organized ourselves.

You’ll see:
- Key numbers and platform growth
- New DrugCard modules launched in 2025
- Conferences, events, and community activities we took part in

Thank you to our clients, partners, and the entire DrugCard community for being part of this journey. We’re excited to keep building in 2026✨

2025 was a year of growth, learning, and building for DrugCard.In this video, we share DrugCard’s 2025 results in numbers — from key platform metrics and pro...